# Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG

> **NCT02916979** · PHASE1 · COMPLETED · sponsor: **Dartmouth-Hitchcock Medical Center** · enrollment: 20 (actual)

## Conditions studied

- Leukemia, Lymphoid
- Leukemia, Myeloid
- Myelodysplastic Syndromes
- Myelofibrosis
- Lymphoma, Malignant
- Multiple Myeloma
- Waldenstrom Macroglobulinemia

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Busulfan
- **BIOLOGICAL:** Rabbit ATG
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT02916979
- **Lead sponsor:** Dartmouth-Hitchcock Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-06
- **Primary completion:** 2019-06-07
- **Final completion:** 2022-02-11
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02916979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02916979, "Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02916979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*